摘要
目的:比较布地格福吸入气雾剂与布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病(COPD)稳定期患者的效果。方法:选取2022年4月至2023年6月于该院诊的90例COPD稳定期患者进行前瞻性研究,使用随机数字表法将其分为对照组和观察组各45例。对照组采用布地奈德福莫特罗粉吸入剂治疗,观察组采用布地格福吸入气雾剂治疗,比较两组临床疗效,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC]水平、呼吸困难症状[圣乔治呼吸问卷(SGRQ)]评分、COPD症状[COPD患者自我评估问卷(CAT)]评分、6min步行[6 min步行试验(6MWT)]距离、生命质量[生活质量综合评定问卷-74(GQOLI-74)]评分和不良反应发生率。结果:观察组治疗总有效率为95.56%(43/45),高于对照组的75.56%(34/45),差异有统计学意义(P<0.05);治疗后,观察组FEV_(1)、FVC和FEV_(1)/FVC水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组SGRQ、CAT评分均低于对照组,6MWT距离长于对照组,差异有统计学意义(P<0.05);治疗后,观察组心理、躯体、社会功能和物质生活等GQOLI-74评分均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:布地格福吸入气雾剂治疗COPD稳定期患者可提高治疗总有效率、肺功能指标水平、6MWT距离和生命质量评分,降低呼吸困难症状评分和COPD症状评分,效果优于布地奈德福莫特罗粉吸入剂治疗。
Objective:To compare effects of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol and Budesonide Formoterol powder inhalation in treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 90 patients with stable COPD who were diagnosed in this hospital from April 2022 to June 2023.They were divided into control group and observation group by using the random number table method,45 cases in each group.The control group was treated with Budesonide Formoterol powder inhalation,while the observation group was treated with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol.The clinical efficacy,the lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1)),FEV_(1)/FVC]levels,the dyspnea symptoms[St.George’s respiratory questionnaire(SGRQ)]score,the COPD symptoms[COPD assessment test(CAT)]score,the 6 min walking[6 min walking test(6MWT)]distance,the quality of life[general quality of life comprehensive invetory-74(GQOLI-74)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 95.56%(43/45),which was higher than 75.56%(34/45)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FEV_(1),FVC and FEV_(1)/FVC in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the SGRQ and CAT scores of the observation group were lower than those of the control group,the 6MWT distance was longer than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the GQOLI-74 scores of psychological,physical,social function and material life in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol in the treatment of the patients with stable COPD can improve the total effective rate of treatment,the lung function index levels,the 6MWT distance and the quality of life scores,and reduce the dyspnea symptom scores and the COPD symptom scores.Moreover,it is superior to single Budesonide Formoterol powder inhalation treatment.
作者
郑凡
徐慧
雷煌平
ZHENG Fan;XU Hui;LEI Huangping(The Second People’s Hospital of Jingdezhen,1.Pharmaceutical Department,2.Department of Respiratory Medicine,Jingdezhen 333000 Jiangxi,China)
出处
《中国民康医学》
2024年第11期122-125,共4页
Medical Journal of Chinese People’s Health
基金
景德镇市科技计划项目(20231SFZC063)。
关键词
慢性阻塞性肺疾病
稳定期
布地格福吸入气雾剂
布地奈德福莫特罗粉吸入剂
肺功能
生命质量
症状
Chronic obstructive pulmonary disease
Stable period
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate inhalation aerosol
Budesonide Formoterol powder inhalation
Lung function
Quality of life
Symptom
